Importancia del uso del surfactante pulmonar en el síndrome de membrana hialina en prematuros menores de 28 semanas, Hospital IESS Babahoyo periodo mayo-septiembre 2019.

Hyaline Membrane Disease (EMH) is known for its deficiency or lack of pulmonary surfactant in the premature neonate, it is one of the main and important causes of morbidity and mortality in neonates. Exogenous pulmonary surfactant has been revolutionized as a treatment for this entity in developed countries, although its benefit has been lower in developing countries. The administration of this surfactant has been a milestone in the history of newborns (RN). It is a recent, notorious and historical advance in neonatal intensive care. It is compared with the introduction of insulin and penicillin in their respective specialties. Although we Know that the discovery of pulmonary surfactant is associated with the treatment of type 1 Respiratory Distress Syndrome known as hyaline membrane syndrome in preterm infants, and the natural history of this disease has changed, today its indications have been differentiated. Since the application of surfactant for the first time, multiple studies have been published regarding effectiveness, efficiency, adverse effects, ventilatory strategies used and modes of administration. Comprehensive care of the newborn and the care of health professionals are essential before, during and after administration to achieve its effectiveness. Future clinical and pharmacological research will demonstrate the usefulness of new surfactants, new forms of administration and new indications for the health of neonates.

• Үндсэн зохиолч: Acero Guerrero, Karen Michelle (author)
• Бусад зохиолчид: Chávez García, Gloria Jennifer (author)
• Формат: bachelorThesis
• Хэл сонгох: spa
• Хэвлэсэн: 2019
• Нөхцлүүд: Surfactante Pulmonar; Síndrome de Membrana Hialina; Prematuros
• Онлайн хандалт: http://dspace.utb.edu.ec/handle/49000/6956